Ulocuplumab (BMS-936564) is a mAb against CXCR4, and is currently in phase Ib/II study to determine its safety and tolerability for patients with relapsed/refractory multiple myeloma (20). This evidence concerns the gene CXCR4 and plasma cell myeloma.